Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03073265 · ClinicalTrials.gov registry record
Apixaban Validation Study - Additional Study on Fresh Samples
A clinical trial of Anticoagulation With Apixaban, sponsored by Diagnostica Stago.
- Completed
- Registry status
- 109
- Enrollment target
- 2
- Study locations
NCT03073265 is a study of Anticoagulation With Apixaban that has completed, run by Diagnostica Stago. The registered enrollment target is 109 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT03073265, a study of Anticoagulation With Apixaban, has completed, sponsored by Diagnostica Stago.
- COMPLETED
- Registry status
- 109 participants
- Enrollment target
- 2
- Study locations
Study Summary
The objective is to demonstrate the performances of STA® - Apixaban Calibrator \& STA® - Apixaban Control used in combination with STA® - Liquid Anti-Xa to measure apixaban concentration in plasma. Anti-Xa results will be compared to LCMS (liquid chromatography - mass spectrometry) for validation of the assay. For this study, the anti-Xa assay will be performed on fresh samples only. The results will be used to complete results obtained previously on frozen samples.
Conditions Studied
Interventions
- DEVICE STA-Apixaban Calibrator & Control
Study Locations (2)
North Carolina
- Moses Cone Memorial Hospital - Greensboro
Pennsylvania
- Lehigh Valley Health Nrwork - Allentown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2017-05-08 |
| Est. Completion | 2017-11-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03073265
The ClinicalTrials.gov registry entry for NCT03073265 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 109 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Diagnostica Stago, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Anticoagulation With Apixaban appearing as the primary indexed condition, and to 1 intervention - of which STA-Apixaban Calibrator & Control is the first listed.
NCT03073265 reports 2 study locations spanning 2 distinct geographic areas - top geographies include North Carolina, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03073265 about?
NCT03073265 is a clinical study titled "Apixaban Validation Study - Additional Study on Fresh Samples". The objective is to demonstrate the performances of STA® - Apixaban Calibrator \& STA® - Apixaban Control used in combination with STA® - Liquid Anti-Xa to measure apixaban concentration in plasma. Anti-Xa results will be compared to LCMS (liquid chromatography - mass spectrometry) for validation of...
What is the current status of trial NCT03073265?
This trial is currently completed. The enrollment target is 109 participants. The study started on 2017-05-08. Estimated completion is 2017-11-01.
What conditions does trial NCT03073265 study?
This clinical trial studies the following conditions: Anticoagulation With Apixaban.
What interventions are being tested in trial NCT03073265?
The interventions under investigation include: STA-Apixaban Calibrator & Control (DEVICE).
Who is sponsoring clinical trial NCT03073265?
This trial is sponsored by Diagnostica Stago, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03073265 being conducted?
This trial has 2 study locations across North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.